Gene therapy for diabetic foot ulcers: Interim analysis of a randomised, placebo-controlled phase 3 study of VM202 (ENGENSIS), a plasmid DNA expressing two isoforms of human hepatocyte growth factor.

Engensis (donaperminogene seltoplasmid) - Beijing Northland, Reyon Pharma, Helixmith

http://www.ncbi.nlm.nih.gov/pubmed/37230802

May 26, 2023